Halozyme Therapeutics Inc (HALO)

Current ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Total current assets	US$ in thousands	746,424	879,006	765,745	615,019	739,013	653,201	541,938	988,689	926,287	1,017,300	999,750	941,719	554,764	498,895	500,358	467,971	543,436	342,041	391,706	409,036
Total current liabilities	US$ in thousands	112,494	115,185	116,393	91,919	130,789	109,384	199,512	111,691	117,147	113,153	114,251	107,421	421,385	26,976	26,073	42,002	85,637	108,041	135,417	138,662
Current ratio		6.64	7.63	6.58	6.69	5.65	5.97	2.72	8.85	7.91	8.99	8.75	8.77	1.32	18.49	19.19	11.14	6.35	3.17	2.89	2.95

December 31, 2023 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $746,424K ÷ $112,494K
= 6.64

The current ratio for Halozyme Therapeutics Inc. has fluctuated over the past eight quarters, ranging from a low of 2.72 in Q2 2022 to a high of 8.85 in Q1 2022. The ratio reflects the company's ability to cover its short-term liabilities with its current assets, with a higher ratio indicating a stronger liquidity position.

In the most recent quarter, Q4 2023, the current ratio stands at 6.64, which indicates a healthy liquidity position. This suggests that the company has sufficient current assets to meet its short-term obligations. However, it is noteworthy that there has been some variability in the current ratio over the past quarters, which could be due to fluctuations in current assets or liabilities.

Overall, Halozyme Therapeutics Inc. appears to have maintained a relatively strong current ratio in recent quarters, which provides some assurance of its ability to meet its short-term financial obligations. However, investors and analysts should continue to monitor this ratio to ensure the company's liquidity remains stable and sustainable.